Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that Executive Chairman and CEO Dr. Raza Bokhari, along with the members of the Company's Board of Directors, members of the leadership team, investors, advisors and other stakeholders, will ring the Toronto Stock Exchange (TSX) opening bell on Thursday, October 26^th 2023, at 9:30 am ET.

The Opening Bell Ringing Ceremony will be held at the TSX Market Centre in Toronto and will be webcast live beginning at 9:20 am ET at .

The Company also announced the appointment of Paul A Marchetto, MD, FACS as the Chairman of the Scientific Advisory Board of the Company.

Dr. Marchetto was on the medical staff of the Rothman Institute as an orthopedic and a sports medicine surgeon. He has previously also worked for the Philadelphia Eagles Team Orthopedic Surgeon and was the associate professor of orthopedic surgery at Thomas Jefferson University in Philadelphia and the Vice Chairman of Orthopedics, Sidney Kimmel Medical College, Thomas Jefferson University. He has served as the head team physician for Rutgers University-Camden and as the assistant team orthopedist for the Philadelphia Flyers. Dr. Marchetto completed his orthopedic residency training at the Albert Einstein Medical Center in Philadelphia and his fellowship in sports medicine at Temple University Hospital.

"It will be a special honor for me to ring the opening bell at Toronto Stock exchange to commence trading in the presence of Medicus Pharma's extended family and friends," said Dr. Raza Bokhari, Executive Co-Chairman and CEO. "The recent listing of our common shares on TSX venture exchange is a momentous milestone in our journey to assemble a world class team, advance novel therapies and create positive shareholder value. The addition of Dr. Marchetto to lead and expand our scientific advisory board is yet another example of the world class team we are assembling. We will immensely benefit from his leadership and experience to help shape our Pharma R&D and acquisition strategy."

For further information contact:

Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

About Medicus Pharma Ltd:

Medicus Pharma Ltd. (TSXV: MDCX) is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization.

Skinject Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes future-oriented financial information with respect to prospective financial performance, financial position or cash flows that is presented as a forecast or a projection. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on SEDAR+, which may impact, among other things, the Company's ability to advance SkinJect's R&D programs, and potentially identify and invest in additional bio-technology targets. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Prospectus accessible on the Company's profile on SEDAR+ at . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

To view the source version of this press release, please visit